Oops! Incremental Buy
Just noticed that I made a trade in my account and forgot to let you know … mostly because I didn’t notice that the trade happened (it was a small limit order I had in, and it triggered while I was...
View ArticleBenjamin Shepherd’s “Black Rock Fuel”
I haven’t written about Benjamin Shepherd’s Global Investment Strategist in quite a long time, so when folks started asking about his pitch for “Black Rock Fuel” I thought I’d take a look for you — and...
View ArticleBrazilian Burgers, Mongolian Real Estate, Africa and Ligand
Before I get churning with this week’s Friday File, I want to take the opportunity to thank you, the Irregulars — and particularly the several new members we’ve had join up as Irregulars in the last...
View Article“Three Biotechs Beating the House”
The following was originally published, along with this companion article, in late February. Louis Navellier is again pushing exactly the same ad teasing the same three biotech stocks, over the last...
View ArticlePoints of Consideration for Ligand
Those who are Irregulars know that I own shares of Ligand (LGND) and suggested it last summer in the mid-$30s, and have nibbled personally on the way up. My reasons for liking Ligand are basically two:...
View Article“Ellis White’s $12 Billion Oil Map” revealed, plus some portfolio updates and...
For our Friday File fun today I’ve got a couple udpated thoughts and check-ins on some companies that I follow and have written to you about before, but I also always like to toss in a teaser solution...
View ArticleDecent Early Indications for LGND
Just a quick note that GlaxoSmithKline released results yesterday — for those who are interested in Ligand, which I own and have written about several times over the past year, the Promacta news looked...
View ArticleFriday File — Casey’s “Important News” flop and some updates on favorites
This week there’s been quite a bit of news in stocks that I follow fairly closely or own or have featured in the past as “Idea of the Month” candidates for the irregulars, so I do have a bit of a...
View Article“Best Energy Stocks Under $1″ from Kent Moors … and Some Updates
I’ve got a few thoughts on stocks I follow and on a portfolio move I made today to shave my risk profile a little bit, but first I thought I’d take a quick gander at the latest teaser pitch from Dr....
View ArticleMiscellaneous Thoughts and Updates for the Friday File
I’m going to keep it brief for you today — and we’re not going to have a formal “Idea of the Month” piece for October because, well, we’re at the end of October and I haven’t recently come across a new...
View ArticleAnnual Review
All of you, dear Irregulars, know that Stock Gumshoe is not a “tip sheet,” and I don’t operate a portfolio for other people to emulate or copy, or even attempt to track the stocks we cover as if they...
View Article“Lifetime Payouts” from Obamacare… plus some Friday File portfolio updates
I have a few updates for you this week — there was a little bit of earnings news in the Gumshoe Universe, and I did a little rebalancing in my portfolio to get cash levels up in anticipation of future...
View ArticleCisco, Chang & Charlie
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his past articles...
View ArticleUpdates: Peanuts, Ligand, Oil, Insurance and Healthcare
I’ve got a teaser solution writeup for you this week too, a little stock, but I’m still working on that and I’ve got some other Friday thoughts available for you now, so we’re going to split your...
View ArticleIdea of the Month: Buy What Buffett Won’t
We were talking about Warren Buffett just yesterday, and I also recently was looking into flights to go to the annual meeting in the Spring, so everyone’s favorite avuncular billionaire was on my mind...
View ArticleIrregulars Annual Review
Each year I go through all of the stocks that I either own personally or have brought to the attention of the Irregulars (there’s quite a bit of overlap on those lists), and I make sure to update my...
View ArticleWhat’s the “Drug Royalty Program” that Sid Riggs says “Averages 180% Per Year?”
This percolated up to the “most asked about” teaser pitch over the weekend, and it’s easy to see why — everyone loves royalties (or as the newsletters like to call it, “getting money for free without...
View ArticleOops! Incremental Buy
Just noticed that I made a trade in my account and forgot to let you know … mostly because I didn’t notice that the trade happened (it was a small limit order I had in, and it triggered while I was...
View ArticleBrazilian Burgers, Mongolian Real Estate, Africa and Ligand
Before I get churning with this week’s Friday File, I want to take the opportunity to thank you, the Irregulars — and particularly the several new members we’ve had join up as Irregulars in the last...
View ArticlePoints of Consideration for Ligand
Those who are Irregulars know that I own shares of Ligand (LGND) and suggested it last summer in the mid-$30s, and have nibbled personally on the way up. My reasons for liking Ligand are basically two:...
View Article
